Format

Send to

Choose Destination
Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8.

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Author information

1
Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec, Canada.

Abstract

The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.

PMID:
10406640
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center